UCSF Performs World's First OnQ Prostate-Assisted Robotic HIFU Procedure
• Cortechs.ai and EDAP TMS SA achieved a milestone with the first-ever OnQ Prostate-assisted Focal One Robotic HIFU procedure performed at UCSF Prostate Center.
• UCLA researchers found that early radiation therapy side effects in prostate cancer patients may indicate higher risks of serious long-term urinary and bowel complications.
• Vanderbilt researchers discovered that the inherited mutated WNT9B gene, crucial in embryonic prostate development, increases adult prostate cancer risk.
EDAP TMS Treats First Patient with HIFU in Pancreatic Cancer Trial
• EDAP TMS SA has initiated a Phase I/II trial (PULS) using High Intensity Focused Ultrasound (HIFU) for pancreatic tumor treatment.
• The first patient with locally advanced pancreatic cancer was treated successfully in the PULS trial, showing tolerance to the HIFU intervention.
• The PULS trial aims to evaluate both the tolerance and preliminary efficacy of intraoperative HIFU for unresectable pancreatic tumors.
• This milestone reflects EDAP's commitment to innovative therapies for areas of significant unmet medical need, like pancreatic cancer.
EDAP TMS Announces First Patients Treated in Phase I/II Study of Focal One HIFU for Benign Prostatic Hyperplasia
• EDAP TMS has initiated a Phase I/II clinical trial evaluating Focal One robotic HIFU for benign prostatic hyperplasia (BPH) treatment.
• The study aims to determine optimal treatment parameters using Focal One HIFU to improve BPH symptoms with minimal side effects.
• The trial is a prospective, multicenter study conducted in two parts, starting in France and potentially expanding to the United States.
• Focal One's precision in delivering HIFU energy is expected to offer a less invasive BPH treatment option, preserving urethral integrity.
© Copyright 2025. All Rights Reserved by MedPath